Nonetheless, to date no prognostic classification is universally accepted for use in clinical practice or clinical trial conduct.
Between 2014 and 2017 docetaxel and abiraterone acetate were shown to increase the longevity of men commencing ADT for mHSPC. [11] [12] [13] [14] In particular, the CHAARTED trial showed a clear benefit for patients with a high burden of disease. The E3805
investigators defined high volume (HV) disease as the presence of visceral metastases and/or four or more osseous metastases of which at least one extra-axial with the remainder being low volume (LV). 13 Subgroup analyses of patients treated with ADT alone demonstrated that the prospectively defined LV patients and those relapsing with metastases after prior local therapy with curative intent (PLT) had a longer overall survival (OS) compared to patients with HV disease and men with newly diagnosed with mHSPC (de-novo, DN). [15] [16] [17] Identification and use of simple and reliable clinical factors prognostic of survival with ADT would facilitate treatment decision making, clinical trial design, biological interrogations, and personalized therapy. This study aimed to assess whether a classification system based on time of metastatic disease occurrence (PLT or DN) and volume of disease (LV or HV) is prognostic for patients with mHSPC treated with ADT in a prospectively collected hospital-based registry. Figure 2 ).
| MATERIALS AND METHODS
In univariate analysis, while covariates median PSA and pain showed a robust association with both OS and time to CRPC, year of diagnosis <2004 versus >2009 was shown to be associated with a shorter time to CRPC but not to death (Table 3) . Furthermore, patients with node only metastases had a significantly longer OS and time to CRPC compared to bone plus/minus node metastases. Therefore, we further assessed the prognostic properties of the composite risk groups with a multivariable Cox model, adjusted for median PSA, pain, year of diagnosis and extent of disease (Table 4) (Table 4 ).
| DISCUSSION
High metastatic burden and DN presentation are known to be associated with poor prognosis for mHSPC patients treated with ADT. [15] [16] [17] The present study showed that time of metastatic disease shorter survival and time to CRPC was more than double (Table 2) .
These results are consistent with those of the post-hoc analysis of the CHAARTED trial and of the CHAARTED-GETUG-AFU15 combined study. 16, 17 Similarly to our report, in both these analyses, patients were classified by time of metastatic disease occurrence and extent of disease burden and the OS of each of the four groups was evaluated.
Consistently with our study, the PLT/LV cohort experienced the best prognosis with ADT, while DN/HV had the worst outcomes and a halving of survival compared to PLT/LV in the GETUG-AFU15 dataset (34.0 [28.5-43.6] vs NR [69.8-NR] months). 17 Collectively, these results suggest that DN/HV disease is a biologically distinct entity which is less androgen dependent and has a more aggressive phenotype. In our study, some biological evidence is provided by the observation that DN patients have a two-fold higher rate of biopsy GS ≥ 8 (72%) compared to PLT (34%). Besides, absence of pain and ECOG PS = 0 were more common among patients with PLT than DN, 70% and 78% versus 51%
and 65%, respectively, and median PSA at ADT start was notably higher in DN compared to PLT (Table 1) . Furthermore, in both abovementioned post-hoc trial-based analyses, DN/HV was shown to be the only group to benefit from the chemohormonal regimen. While the survival improvement was only numerical in the GETUG-AFU15
analysis, it was statistically significant in the CHAARTED study (HR = 0.63; P = 0.0004). 16, 17 These data further corroborate the hypothesis that DN/HV may be a less testosterone dependent disease for which the addition of chemotherapy to ADT can be more beneficial.
Conversely, there appears to be no benefit of chemotherapy in PLT/LV patients who have a prolonged response to ADT. 16, 17 The intermediate prognostic group, PLT/HV or DN/LV, represents a greyer area as some of these patients may profit from the addition of docetaxel to hormone therapy, which highlights the need of accurate biomarkers for identification, whereas other subjects would probably benefit more from a different treatment. In this respect, while recent data from the 0.49-0.75). [11] [12] Notably, 94% of the STAMPEDE metastatic population had DN disease but, since disease burden in this subgroup was not defined, the classification in LV versus HV cannot be done. In addition, more research focusing on pts with PLT and/or LV disease would be needed to confidently state that the upfront combination of ADT and abiraterone is better than sequential treatment in these unique patient cohorts.
The three prognostic groups identified in the present study may predict distinct outcomes with different therapies and this classification could ultimately be an efficient tool to personalize treatment and avoid unnecessary toxicity. A definitive confirmation could come from future prospective studies which should stratify patients using this prognostic system based on history of prior local therapy and volume of metastases.
In the past, several studies proposed different prognostic classifications for mHSPC treated with ADT. Most of them took into consideration the disease burden, often defined according to the number of metastases on the bone scan 9, 19 or whether axial or extraaxial. 8, 9 While identifying the correct number of metastases can be challenging, especially when confluent, a selection based solely on location may be misleading, especially in case of a solitary appendicular lesion. The Glass prognostic system was based on the latter and other factors, such as ECOG PS, PSA levels, and biopsy GS, validated from a large randomized clinical trial dataset. 9 As in our study, this classification would allow identifying three prognostic groups predictive of survival.
However, a statistical limitation of the Glass classification study was the low R 2 values for the test and validation model (13% and 12%, respectively). Besides, while this classification based on four factors identifies prognostic groups with significantly different outcomes, segregation is not intuitive and lacks the reproducibility necessary for routine clinical use which was observed with our easily applicable model of stratification based on two clinically meaningful factors. Furthermore, in our univariate analysis, ECOG PS and biopsy GS did not result in being independent prognostic factors ( Table 3 ). It could be postulated that both these covariates were trumped by the more potent prognostic factors of time of metastatic disease presentation and volume of disease as these are clinical variables that presumably represent disease biology more accurately. Namely, DN/HV disease is usually rapidly progressive and thus probably represents a more aggressive multiclonal entity compared to PLT/LV.
Conversely, in multivariate analysis, the absence of cancer-related pain at time of start of ADT was confirmed an independent predictive factor of longer survival and time to CRPC for mHSPC patients (Table 3) . However, this association was not as statistically robust as for PLT/LV and data regarding pain were extracted from clinical chart notations rather than from standardized pain assessments, which may limit the validity of this finding. Nevertheless, it should be noted that the absence of cancer-related pain has been found to be significantly related to survival in several studies in the past. 20, 21 The retrospective nature of the present study, the small size of the 
| CONCLUSIONS
The prognostic system based on time of metastatic presentation and E3805 defined volume of disease can be easily applied as a prognostic tool for counseling patients with mHSPC treated with ADT and can be a simple and reproducible stratification system for future clinical trials. 
